7 results
By adding Cetuximab to standard treatment, we hope to prolonge progression free survival
The primary objective of this trial is to determine if EMD 1201081 (formerly known as IMO-2055) has anti-tumor activity in subjects by examining its effects on accepted clinical endpoints in combination with cetuximab. • To evaluate progression-free…
Part 1 (phase 1b): to identify a dose of AMG 655 in combination with doxorubicin that is safe and tolerated as determined by the incidence of dose limiting toxicity Part 2 (phase2): To estimate the efficacy, as measured by progression-free survival…
The aim of this study is to compare the effect of a postoperativenegative pressure dressing (Prevena (TM) IMS) with a standardwound dressing (care as usual) in clean closed surgical wounds on the prevention of wounddehiscence in low riks and high…
EFFICACY OBJECTIVESWithin each cohort, the study has the following co-primary efficacy objectives:· Assessing early efficacy during the Maintenance Treatment Phase based on a 20%reduction in tumour size after 2 months of treatment· Evaluating PFSThe…
Primary objectives:The primary objectives are to evaluate the feasibility of oral administration of bevacizumab-800CW and cetuximab-800CW for detection of neoplasia in BE patients compared to HD-WLE to shorten the qFME procedure and test whether…
The purpose of this Safety Lead In study is to explore if encorafenib and cetuximab in combination with a chemotherapy regimen (either mFOLFOX6 or FOLFIRI) are safe and have beneficial effects on you and your colorectal cancer. This is a small…